Blue flash ERG PhNR changes associated with poor long-term glycemic control in adolescents with type 1 diabetes

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 2, 2012, Pages 741-748

  McFarlane, Michelle ^a   Wright, Tom ^a   Stephens, Derek ^a,b   Nilsson, Josefin ^c   Westall, Carol A ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

A WAVE; ADOLESCENT; ADULT; ARTICLE; B WAVE; BLUE LIGHT; CLINICAL ARTICLE; CONTRAST SENSITIVITY; CONTROLLED STUDY; ELECTRORETINOGRAPHY; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIGHT ADAPTATION; MALE; OUTCOME ASSESSMENT; PHOTOPIC NEGATIVE RESPONSE; PRIORITY JOURNAL; RETINA CONE; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; WHITE LIGHT; CASE CONTROL STUDY; CHILD; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RISK FACTOR;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; FEMALE; HUMANS; MALE; RETINA; RETINAL CONE PHOTORECEPTOR CELLS; RISK FACTORS; YOUNG ADULT;

EID: 84859242584     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8263     Document Type: Article

References (81)

1. Klein R, Knudtson M, Lee K, Gangnon R, Klein B. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII. The twenty-five- year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859-1868.
2. Klein R, Klein B, Moss S, Davis M, DeMets D. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520-526.
3. LeCaire T, Palta M, Zhang H, Allen C, Klein R, D'Alessio D. Lowerthan-expected prevalence and severity of retinopathy in an incident cohort followed during the first 4-14 years of type 1 diabetes: the Wisconsin Diabetes Registry Study. Am J Epidemiol. 2006;164: 143-150.
4. International Diabetes Federation (IDF). Diabetes in the Young: a Global Perspective. The Diabetes Atlas. Brussels, Belgium: IDF; 2011.
5. ETDRS. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98: 786-806.
6. Hood D, Benimoff N, Greenstein V. The response range of the blue-cone pathways: a source of vulnerability to disease. Invest Ophthalmol Vis Sci. 1984;25:864-867.
7. Greenstein VC, Hood DC, Ritch R, Steinberger D, Carr RE. S (blue) cone pathway vulnerability in retinitis pigmentosa, diabetes and glaucoma. Invest Ophthalmol Vis Sci. 1989;30:1732-1737.
8. Greenstein V, Sarter B, Hood D, Noble K, Carr R. Hue discrimination and S cone pathway sensitivity in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1990;31:1008-1014.
9. Swanson W, Birch D, Anderson J. S-cone function in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1993;34:3045-3055.
10. Daley M, Watzke R, Riddle M. Early loss of blue-sensitive color vision in patients with type I diabetes. Diabetes Care. 1987;10: 777-781.
11. Muntoni S, Serra A, Mascia C, Songini M. Dyschromatopsia in diabetes mellitus and its relation to metabolic control. Diabetes Care. 1982;5:375-378.
12. Kurtenbach A, Wagner U, Neu A, Schiefer U, Ranke MB, Zrenner E. Brightness matching and colour discrimination in young diabetics without retinopathy. Vision Res. 1994;34:115-122.
13. Kurtenbach A, Schiefer U, Neu A, Zrenner E. Preretinopic changes in the colour vision of juvenile diabetics. Br J Ophthalmol. 1999; 83:43-46.
14. Terasaki H, Hirose H, Miyake Y. S-cone pathway sensitivity in diabetes measured with threshold versus intensity curves on flashed backgrounds. Invest Ophthalmol Vis Sci. 1996;37:680-684.
15. Bresnick G, Condit R, Palta M, Korth K, Groo A, Syrjala S. Association of hue discrimination loss and diabetic retinopathy. Arch Ophthalmol. 1985;103:1317-1324.
16. Marmor M, Cabael L, Shukla S, Hwang J, Marcus M. Clinical S-cone ERG recording with a commercial hand-held full-field stimulator. Doc Ophthalmol. 2004;109:101-107.
17. Chiti Z, North R, Mortlock K, Drasdo N. The S-cone electroretinogram: a comparison of techniques, normative data and age-related variation. Ophthalmic Physiol Opt. 2003;23:370-376.
18. Arden G, Wolf J, Berninger T, Hogg C, Tzekov R, Holder G. S-cone ERGs elicited by a simple technique in normals and in tritanopes. Vision Res. 1999;39:641-650.
19. Simonsen S, Rosenberg T. Reappraisal of a short-wavelength-sensitive (S-cone) recording technique in routine clinical electroretinography. Doc Ophthalmol. 1995;91:323-332.
20. Gouras P, MacKay C. Electroretinographic responses of the short-wavelength- sensitive cones. Invest Ophthalmol Vis Sci. 1990;31: 1203-1209.
21. Sawusch M, Pokorny J, Smith V. Clinical electroretinography for short wavelength sensitive cones. Invest Ophthalmol Vis Sci. 1987;28:966-974.
22. Yamamoto S, Kamiyama M, Nitta K, Yamada T, Hayasaka S. Selective reduction of the S cone electroretinogram in diabetes. Br J Ophthalmol. 1996;80:973-975.
23. Yamamoto S, Takeuchi S, Kamiyama M. The short wavelengthsensitive cone electroretinogram in diabetes: relationship to systemic factors. Doc Ophthalmol. 1997;94:193-200.
24. Mortlock K, Chiti Z, Drasdo N, Owens D, North R. Silent substitution S-cone electroretinogram in subjects with diabetes mellitus. Ophthalmic Physiol Optic. 2005;25:392-399.
25. Drasdo N, Aldebasi Y, Chiti Z, Mortlock K, Morgan J, North R. The S-cone PHNR and pattern ERG in primary open angle glaucoma. Invest Ophthalmol Vis Sci. 2001;42:1266-1272.
26. Wakili N, Horn F, Jünemann A, et al. The photopic negative response of the blue-on-yellow flash-electroretinogram in glaucomas and normal subjects. Doc Ophthalmol. 2008;117:147-154.
27. Viswanathan S, Frishman L, Robson J, Harwerth R, Smith E 3rd. The photopic negative response of the macaque electroretinogram: reduction by experimental glaucoma. Invest Ophthalmol Vis Sci. 1999; 40:1124-1136.
28. Viswanathan S, Frishman L. Evidence that negative potentials in the photopic electroretinograms of cats and primates depend upon spiking activity of retinal ganglion cell axons (abstract). Soc Neurosci. 1997;123:1024.
29. Lopes de Faria J, Russ H, Costa V. Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy. Br J Ophthalmol. 2002;86:725-728.
30. Zhang L, Ino-ue M, Dong K, Yamamoto M. Retrograde axonal transport impairment of large-and medium-sized retinal ganglion cells in diabetic rat. Curr Eye Res. 2000;20:131-136.
31. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J Physiol. 2008;586:4401-4408.
32. Qin Y, Xu G, Wang W. Dendritic abnormalities in retinal ganglion cells of three-month diabetic rats. Curr Eye Res. 2006;31:967-974.
33. Van Dijk HW, Kok PHB, Garvin M, et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50:3404-3409.
34. Oshitari T, Hanawa K, Adachi-Usami E. Changes of macular and RNFL thicknesses measured by Stratus OCT in patients with early stage diabetes. Eye (Lond). 2009;23:884-889.
35. Ozdek S, Lonneville YH, Onol M, Yetkin I, Hasanreisoglu BB. Assessment of nerve fiber layer in diabetic patients with scanning laser polarimetry. Eye (Lond). 2002;16:761-765.
36. The effects of intensive diabetes treatment on the development and progression of longterm complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. N Engl J Med. 1993;329:977-986.
37. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin- dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr. 1994;125:177-188.
38. Daneman D, Wolfson DH, Becker DJ, Drash AL. Factors affecting glycosylated hemoglobin values in children with insulin-dependent diabetes. J Pediatr. 1981;99:847-853.
39. Mortensen H, Villumsen J, Vølund A, Petersen K, Nerup J. Relationship between insulin injection regimen and metabolic control in young Danish type 1 diabetic patients. Diabet Med. 1992;9: 834-839.
40. Klein B, Moss S, Klein R. Is menarche associated with diabetic retinopathy? Diabetes Care. 1990;13:1034-1038.
41. Murphy R, Nanda M, Plotnick L, Enger C, Vitale S, Patz A. The relationship of puberty to diabetic retinopathy. Arch Ophthalmol. 1990;108:215-218.
42. Klemp K, Larsen M, Sander B, Vaag A, Brockhoff P, Lund-Andersen H. Effect of short-term hyperglycemia on multifocal electroretinogram in diabetic patients without retinopathy. Invest Ophthalmol Vis Sci. 2004;45:3812-3819.
43. Klemp K, Sander B, Brockhoff P, Vaag A, Lund-Andersen H, Larsen M. The multifocal ERG in diabetic patients without retinopathy during euglycemic clamping. Invest Ophthalmol Vis Sci. 2005;46: 2620-2626.
44. Kizawa J, Machida S, Kobayashi T, Gotoh Y, Kurosaka D. Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy. Jpn J Ophthalmol. 2006;50:367-373.
45. Machida S, Gotoh Y, Tanaka M, Tazawa Y. Predominant loss of the photopic negative response in central retinal artery occlusion. Am J Ophthalmol. 2004;137:938-940.
46. Gotoh Y, Machida S, Tazawa Y. Selective loss of the photopic negative response in patients with optic nerve atrophy. Arch Ophthalmol. 2004;122:341-346.
47. Wright S. Adjusted p-values for simultaneous inference. Biometrics. 1992;48:1005-1013.
48. Dunteman G, Ho M. An introduction to generalized linear models. San Francisco: Sage Publications; 2006:1-15.
49. Hosmer D, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons;1989.
50. CDA. Clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes. 2008; 32:S1-S201.
51. Lutze M, Bresnick G. Lenses of diabetic patients "yellow" at an accelerated rate similar to older normals. Invest Ophthalmol Vis Sci. 1991;32:194-199.
52. Gouras P, MacKay C, Yamamoto S. The human S-cone electroretinogram and its variation among subjects with and without L and M-cone function. Invest Ophthalmol Vis Sci. 1993;34:2437-2442.
53. Park S, Sun H, Lee H, Park T, Ohn Y. The role of electroretinography in assessing the progression of diabetic retinopathy. Journal of the Korean Ophthalmological Society. 2010;51:693-699.
54. Nilsson J, Wright T, Westall C. A promising S-cone isolating protocol (abstract). Doc Ophthalmol. 2008;117:40.
55. Sharpe LT, Stockman A. Rod pathways: the importance of seeing nothing. Trends Neurosci. 1999;22:497-504.
56. Henson D, North R. Dark adaptation in diabetes mellitus. Br J Ophthalmol. 1979;63:539-541.
57. Phipps JA, Yee P, Fletcher EL, Vingrys AJ. Rod photorecepto dysfunction in diabetes: activation, deactivation, and dark adaptation. Invest Ophthalmol Vis Sci. 2006;47:3187-3194.
58. Ostroy SE, Frede SM, Wagner EF, Gaitatzes CG, Janle EM. Decreased rhodopsin regeneration in diabetic mouse eyes. Invest Ophthalmol Vis Sci. 1994;35:3905-3909.
59. Greenstein VC, Thomas SR, Blaustein H, Koenig K, Carr RE. Effects of early diabetic retinopathy on rod system sensitivity. Optom Vis Sci. 1993;70:18-23.
60. Gastinger M, Kunselman A, Conboy E, Bronson S, Barber A. Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice. Invest Ophthalmol Vis Sci. 2008; 49:2635-2642.
61. Calkins D. Color vision: from genes to perception. In: Gengenfurtner K, Sharpe L, eds. Color Vision: from Genes to Perception. New York: Cambridge University Press; 1999:163-180.
62. Li Q, Puro D. Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Invest Ophthalmol Vis Sci. 2002;43: 3109-3116.
63. Lucas D, Newhouse J. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol. 1957;58: 193-201.
64. Linsenmeier RA, Braun RD, McRipley MA, et al. Retinal hypoxia in long-term diabetic cats. Invest Ophthalmol Vis Sci. 1998;39:1647-1657.
65. Kawagishi T, Nishizawa Y, Emoto M, et al. Impaired retinal artery blood flow in IDDM patients before clinical manifestations of diabetic retinopathy. Diabetes Care. 1995;18:1544.
66. Feke G, Buzney S, Ogasawara H, et al. Retinal circulatory abnormalities in type 1 diabetes. Invest Ophthalmol Vis Sci. 1994;35: 2968-2975.
67. Bursell S, Clermont A, Kinsley B, Simonson D, Aiello L, Wolpert H. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci. 1996;37:886-897.
68. Alder V, Constable I. Effect of hypoxia on the maintained firing rate of retinal ganglion cells. Invest Ophthalmol Vis Sci. 1981;21: 450-456.
69. Nathan D, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine R. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473-1478.
70. Wilson DM, Kollman C, Xing D, et al. Relationship of A1c to glucose concentrations in children with type 1 diabetes: assessments by high frequency glucose determinations by sensors. Diabetes Care. 2008;31:381-385.
71. Tahara Y, Shima K. The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care. 1993;16:1313-1314.
72. Goldstein D, Little R, Wiedmeyer H, England J, Rohlfing C. Glycohemoglobin testing in diabetes mellitus: assay methods and clinical interpretation. Drugs in Development 1: 253-267.
73. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005;19:178-181.
74. Hirsch IB, Brownlee M. Beyond hemoglobin A1c - need for additional markers of risk for diabetic microvascular complications. JAMA. 2010;303:2291-2292.
75. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med. 1998;15:188-193.
76. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia. 2003; 46(suppl 1):M9-M16.
77. Kilpatrick E, Rigby A, Atkin S. For debate. Glucose variability and diabetes complication risk: we need to know the answer. Diabet Med. 2010;27:868-871.
78. Service F, Molnar G, Rosevear J, Ackerman E, Gatewood L, Taylor W. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19:644-655.
79. McCall A, Cox D, Crean J, Gloster M, Kovatchev B. A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. Diabetes Technol Ther. 2006;8:644-653.
80. Kovatchev B, Cox D, Gonder-Frederick L, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care. 1998;21:1870-1875.
81. Molnar G, Taylor W, Ho M. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972;8:342-348.